Bluejay Diagnostics, Inc. (BJDX): Price and Financial Metrics
GET POWR RATINGS... FREE!
BJDX Stock Price Chart Interactive Chart >
BJDX Price/Volume Stats
| Current price | $1.22 | 52-week high | $6.25 |
| Prev. close | $1.15 | 52-week low | $0.82 |
| Day low | $1.15 | Volume | 160,719 |
| Day high | $1.28 | Avg. volume | 875,877 |
| 50-day MA | $1.13 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 24.62M |
Bluejay Diagnostics, Inc. (BJDX) Company Bio
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX News From Around the Web
Below are the latest news stories about Bluejay Diagnostics Inc that investors may wish to consider to help them evaluate BJDX as an investment opportunity.
Dawson James Thinks Bluejay Diagnostics’ Stock is Going to RecoverIn a report issued on January 31, Jason Kolbert from Dawson James maintained a Buy rating on Bluejay Diagnostics (BJDX – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $1.21, close to its 52-week low of $1.13. According to TipRanks.com, Kolbert is a 3-star analyst with an average return of 2.3% and a 39.2% success rate. Kolbert covers the Healthcare sector, focusing on stocks such as Brainstorm Cell Therapeutics, Citius Pharmaceuticals, and Sorrento Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bluejay Diagnostics with a $10.00 average price target. |
Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDAACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that it has filed a Pre-Submission package for the Symphony IL-6 Test with the U.S. Food and Drug Administration (“FDA” or “the agency”). The purpose of this filing is to request feedback from the agency p |
Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical CareThis Study performs unique rapid on-site measurement using patient whole blood and positions Company to move forward with multiple initiativesACTON, Mass., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today reported that it has completed 90 subjects in the prospect |
10 Low-Float Penny Stocks for Steel-Gutted InvestorsIf you’re willing to absorb massive risk for the chance of significant upside, these low-float penny stocks could fit the bill. |
Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical AdvisorACTON, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced the appointment of Mark W. Feinberg, M.D. as Chief Medical Advisor. Dr. Feinberg will guide Bluejay’s clinical development programs and provide strategic medical and scientific leadership to the Company. “ |
BJDX Price Returns
| 1-mo | 14.02% |
| 3-mo | 12.96% |
| 6-mo | -53.61% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -52.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...